Table of Contents
ISRN Oncology
Volume 2014 (2014), Article ID 793695, 6 pages
http://dx.doi.org/10.1155/2014/793695
Research Article

The Human Epidermal Growth Factor Receptor 2 Screening Tests for Breast Cancer Suggested by the New Updated Recommendation of the American Society of Clinical Oncology/College of American Pathologists Will Involve a Rise of the In-Situ Hybridization Tests for the European Laboratories of Pathology

Biopathology and Oncology Departments, Institut Jean Godinot, Unicancer, 1 rue du Général Koenig CS80014, 51726 Reims Cedex, France

Received 13 February 2014; Accepted 20 March 2014; Published 22 April 2014

Academic Editors: G. Gatti, G. E. Kim, and T. Yokoe

Copyright © 2014 Christian Garbar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Christian Garbar, Aude-Marie Savoye, Corinne Mascaux, Eva Brabencova, and Hervé Curé, “The Human Epidermal Growth Factor Receptor 2 Screening Tests for Breast Cancer Suggested by the New Updated Recommendation of the American Society of Clinical Oncology/College of American Pathologists Will Involve a Rise of the In-Situ Hybridization Tests for the European Laboratories of Pathology,” ISRN Oncology, vol. 2014, Article ID 793695, 6 pages, 2014. doi:10.1155/2014/793695